Macozinone is a DprE1 inhibitor and is not approved yet. Its safety and efficacy data are still not mature.

**Disease Burden**
In 2021, an estimated 10.6 million people fell ill with TB worldwide, of which 450,000 incident cases of rifampicin-resistant or multidrug-resistant TB. About 1.5 million people die from TB each year. Most of the people who fall ill with TB live in LMICs.

**Service Delivery Enablers**
Macozinone is being developed for use as part of an oral TB treatment. Its companion drugs are still unknown, but may include existing TB medicines, most of which are available as generics, although some are not widely accessible.

**Intellectual Property Landscape**
Primary patent on macozinone has been granted in key countries of manufacture such as India, China and South Africa and is expected to expire in 2031. Secondary patents may be filed.

**Regulatory**
The product is not yet approved by any regulatory authority and there is insufficient data to determine bioequivalence studies requirements or the likelihood of a biowaiver.

**Market**
This medicine is still in the R&D pipeline and therefore little is known about its potential positioning in treatment protocols, pricing, and overall access plans.

**Manufacturing**
There are yet no adequate data to assess manufacturing complexity.